Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

45 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety, Pharmacokinetics, and Pharmacodynamics of CC-90001 (BMS-986360), a c-Jun N-terminal Kinase Inhibitor, in Phase 1 Studies in Healthy Participants.
Ye Y, Gaudy A, Thomas M, Reyes J, Burkhardt B, Horan G, Liu L, Chen J, Ghosh A, Carayannopoulos LN, Tatosian DA, Palmisano M. Ye Y, et al. Among authors: gaudy a. Clin Pharmacol Drug Dev. 2022 Dec;11(12):1394-1404. doi: 10.1002/cpdd.1178. Epub 2022 Oct 18. Clin Pharmacol Drug Dev. 2022. PMID: 36256505 Free PMC article. Clinical Trial.
Safety, Pharmacokinetics, and Antifibrotic Activity of CC-90001 (BMS-986360), a c-Jun N-Terminal Kinase Inhibitor, in Pulmonary Fibrosis.
Horan G, Ye Y, Adams M, Parton A, Cedzik D, Tang S, Brown EA, Liu L, Nissel J, Carayannopoulos LN, Gaudy A, Schafer P, Palmisano M, Ramirez-Valle F. Horan G, et al. Among authors: gaudy a. Clin Pharmacol Drug Dev. 2023 Aug;12(8):779-789. doi: 10.1002/cpdd.1294. Epub 2023 Jun 28. Clin Pharmacol Drug Dev. 2023. PMID: 37378860
First-in-Human, Single- and Multiple-Ascending-Dose Studies in Healthy Subjects to Assess Pharmacokinetics, Pharmacodynamics, and Safety/Tolerability of Iberdomide, a Novel Cereblon E3 Ligase Modulator.
Ye Y, Gaudy A, Schafer P, Thomas M, Weiss D, Chen N, Liu L, Xue Y, Carayannopoulos L, Palmisano M. Ye Y, et al. Among authors: gaudy a. Clin Pharmacol Drug Dev. 2021 May;10(5):471-485. doi: 10.1002/cpdd.869. Epub 2020 Sep 23. Clin Pharmacol Drug Dev. 2021. PMID: 32969202 Free PMC article. Clinical Trial.
Response to upfront azacitidine in juvenile myelomonocytic leukemia in the AZA-JMML-001 trial.
Niemeyer CM, Flotho C, Lipka DB, Starý J, Rössig C, Baruchel A, Klingebiel T, Micalizzi C, Michel G, Nysom K, Rives S, Schmugge Liner M, Zecca M, Schönung M, Baumann I, Nöllke P, Benettaib B, Biserna N, Poon J, Simcock M, Patturajan M, Menezes D, Gaudy A, van den Heuvel-Eibrink MM, Locatelli F. Niemeyer CM, et al. Among authors: gaudy a. Blood Adv. 2021 Jul 27;5(14):2901-2908. doi: 10.1182/bloodadvances.2020004144. Blood Adv. 2021. PMID: 34297046 Free PMC article. Clinical Trial.
45 results